Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function1

Many tumor cells shed specialized membrane vesicles known as exosomes. In this study, we show that pretreatment of mice with exosomes produced by TS/A or 4T.1 murine mammary tumor cells resulted in accelerated growth of implanted tumor cells in both syngeneic BALB/c mice and nude mice. As implanted TS/A tumor cells grew more rapidly in mice that had been depleted of NK cells, we analyzed the effects of the tumor-derived exosomes on NK cells. The tumor-derived exosomes inhibit NK cell cytotoxic activity ex vivo and in vitro as demonstrated by chromium release assays. The treatment of mice with TS/A tumor exosomes also led to a reduction in the percentages of NK cells, as determined by FACS analysis, in the lungs and spleens. Key features of NK cell activity were inhibited, including release of perforin but not granzyme B, as well as the expression of cyclin D3 and activation of the Jak3-mediated pathways. Human tumor cell lines also were found to produce exosomes that were capable of inhibiting IL-2-stimulated NK cell proliferation. Exosomes produced by dendritic cells or B cells did not. The presentation of tumor Ags by exosomes is under consideration as a cancer vaccine strategy; however, we found that pretreatment of mice with tumor exosomes blunted the protective effect of syngeneic dendritic cells pulsed ex vivo with tumor exosomes. We propose that tumor exosomes contribute to the growth of tumors by blocking IL-2-mediated activation of NK cells and their cytotoxic response to tumor cells.

[1]  M. Record,et al.  PLD2 is enriched on exosomes and its activity is correlated to the release of exosomes , 2004, FEBS letters.

[2]  Jaap M Middeldorp,et al.  Localization of the Epstein-Barr virus protein LMP 1 to exosomes. , 2003, The Journal of general virology.

[3]  G. Konjević,et al.  Impaired Perforin-Dependent NK Cell Cytotoxicity and Proliferative Activity of Peripheral Blood T Cells is Associated with Metastatic Melanoma , 2001, Tumori.

[4]  Hans Hengartner,et al.  Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice , 1994, Nature.

[5]  Z. Juranić,et al.  The influence of surgery and anesthesia on lymphocyte functions in breast cancer patients: in vitro effects of indomethacin. , 1999, Neoplasma.

[6]  Laurence Zitvogel,et al.  Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming , 2001, Nature Medicine.

[7]  J. Harris,et al.  Immune cell functions in pancreatic cancer. , 2000, Critical reviews in immunology.

[8]  W. Faigle,et al.  Cells release prions in association with exosomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  L. Zitvogel,et al.  Exosomes for immunotherapy of cancer. , 2003, Advances in experimental medicine and biology.

[10]  R. Kiessling,et al.  Tumor-induced immune dysfunction , 1999, Cancer Immunology, Immunotherapy.

[11]  N. Yang,et al.  Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism , 2000, Cancer Gene Therapy.

[12]  A. Angulo,et al.  Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. , 2004, Tissue antigens.

[13]  D. Curiel,et al.  Hepatic DR5 Induces Apoptosis and Limits Adenovirus Gene Therapy Product Expression in the Liver , 2002, Journal of Virology.

[14]  C. Théry,et al.  Indirect activation of naïve CD4+ T cells by dendritic cell–derived exosomes , 2002, Nature Immunology.

[15]  M. Doubrovin,et al.  Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma 1 , 2003, The Journal of Immunology.

[16]  R. Dummer,et al.  HLA-G and IL-10 expression in human cancer--different stories with the same message. , 2003, Seminars in cancer biology.

[17]  L. Zitvogel,et al.  Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells 1 , 2004, The Journal of Immunology.

[18]  L. Zitvogel,et al.  Tumor-derived exosomes: a new source of tumor rejection antigens. , 2002, Vaccine.

[19]  M. Smyth,et al.  Cutting Edge: Tumor Rejection Mediated by NKG2D Receptor-Ligand Interaction Is Dependent upon Perforin1 , 2002, The Journal of Immunology.

[20]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[21]  D. Taylor,et al.  Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects , 2005, British Journal of Cancer.

[22]  M. Smyth,et al.  NKT cells and tumor immunity—a double-edged sword , 2000, Nature Immunology.

[23]  R. Vallejo,et al.  Perioperative immunosuppression in cancer patients. , 2003, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[24]  R. Strong,et al.  NKG2D and Related Immunoreceptors. , 2004, Advances in protein chemistry.

[25]  J. Trapani,et al.  Cutting Edge: Granzymes A and B Are Not Essential for Perforin-Mediated Tumor Rejection , 2003, The Journal of Immunology.

[26]  M. Kuroki,et al.  SOLUBLE THROMBOSPONDIN-1 SUPPRESSES T CELL PROLIFERATION AND ENHANCES IL-10 SECRETION BY ANTIGEN PRESENTING CELLS STIMULATED WITH PHYTOHEMAGGLUTININ , 2001, Immunological investigations.

[27]  Mamoru Ito,et al.  Perforin‐dependent NK cell cytotoxicity is sufficient for anti‐metastatic effect of IL‐12 , 1999, European journal of immunology.

[28]  O. Silvennoinen,et al.  Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. , 1994, Science.

[29]  F. Foss,et al.  Immunologic mechanisms of antitumor activity. , 2002, Seminars in oncology.

[30]  G. Deichman,et al.  Allogeneic bone‐marrow transfusion suppresses development of lung metastases in osteogenic sarcoma patients after radical surgery , 1993, International journal of cancer.

[31]  David B. Allison,et al.  Novel tumor necrosis factor α-regulated genes in rheumatoid arthritis , 2004 .

[32]  Zhongyu Liu,et al.  Depletion of Collagen II-Reactive T Cells and Blocking of B Cell Activation Prevents Collagen II-Induced Arthritis in DBA/1j Mice , 2002, The Journal of Immunology.

[33]  W. Grizzle,et al.  BXD recombinant inbred mice represent a novel T cell–mediated immune response tumor model , 2002, International journal of cancer.

[34]  P. Musiani,et al.  IL-21 Induces Tumor Rejection by Specific CTL and IFN-γ-Dependent CXC Chemokines in Syngeneic Mice1 , 2004, The Journal of Immunology.

[35]  G. Mufti,et al.  Microenvironment Produced by Acute Myeloid Leukemia Cells Prevents T Cell Activation and Proliferation by Inhibition of NF-κB, c-Myc, and pRb Pathways , 2001, The Journal of Immunology.

[36]  J. Schatzle,et al.  Perforin‐ and Fas‐dependent mechanisms of natural killer cell‐mediated rejection of incompatible bone marrow cell grafts , 2002, European journal of immunology.

[37]  J. Darnell,et al.  Reflections on STAT3, STAT5, and STAT6 as fat STATs. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  H. Hoogsteden,et al.  Proteomic analysis of exosomes secreted by human mesothelioma cells. , 2004, The American journal of pathology.

[39]  E. Chiang,et al.  Correction of Defects Responsible for Impaired Qa-2 Class Ib MHC Expression on Melanoma Cells Protects Mice from Tumor Growth 1 , 2003, The Journal of Immunology.

[40]  Rong-Fong Shen,et al.  Identification and proteomic profiling of exosomes in human urine. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Bubeník,et al.  MHC class I down-regulation: tumour escape from immune surveillance? (review). , 2004, International journal of oncology.

[42]  W. D. Cress,et al.  The Role of Cyclin D3-dependent Kinase in the Phosphorylation of p130 in Mouse BALB/c 3T3 Fibroblasts* , 1998, The Journal of Biological Chemistry.

[43]  W. Leonard,et al.  The role of Stat5a and Stat5b in signaling by IL-2 family cytokines , 2000, Oncogene.

[44]  M. Smyth,et al.  Blastocyst MHC, a Putative Murine Homologue of HLA-G, Protects TAP-Deficient Tumor Cells from Natural Killer Cell-Mediated Rejection In Vivo1 , 2003, The Journal of Immunology.

[45]  H. Schreiber,et al.  Role of TGF‐β in immune‐evasion of cancer , 2001 .

[46]  M. Smyth,et al.  Perforin is a major contributor to NK cell control of tumor metastasis. , 1999, Journal of immunology.

[47]  Zhongyu Liu,et al.  CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. , 2003, The Journal of clinical investigation.

[48]  E. Lotzová,et al.  Role of natural killer cells in cancer. , 1993, Natural immunity.

[49]  M. Miyazaki,et al.  Natural killer cell activity and distant metastasis in rectal cancers treated surgically with and without neoadjuvant chemoradiotherapy. , 2003, Journal of the American College of Surgeons.

[50]  Robert A Kyle,et al.  Myeloma and the newly diagnosed patient: a focus on treatment and management. , 2002, Seminars in oncology.